Reprogramming macrophages has emerged as a significant approach for treating a variety of diseases. Identification of targets for macrophage reprogramming has receoved more and more attention. Creative Biolabs provides the most comprehensive transcriptional analysis to identify targets for macrophage reprogramming. Our scientific team has the necessary expertise and capabilities to provide overall solutions for the identification of targets for macrophage reprogramming, focusing on innovative research.
Reprogramming of macrophages might be more beneficial in eliciting an effective anti-tumor immune response. The reprogramming of macrophages from an M1-like phenotype to an M2-like phenotype, which significantly inhibits the progression of inflammatory and autoimmune diseases, can be induced by IL-4. While, several approaches, including targeting the Toll-like receptor, RNA delivery and antibodies have been tried to switch M2-like macrophages with pro-tumor properties into anti-tumor M1-like macrophages. Moreover, a phenotypic switch from the M2-like phenotype to the M1-like phenotype has been observed upon the addition of M1-polarizing stimuli. Reprogramming of M2-like macrophages into M1-like macrophages by small-molecule compounds is associated with induction of a strong antitumor activity alone or in combination with other therapeutics. Currently, reprogramming M2 to anti-tumorigenic M1 is being extensively studied as a strategy for glioblastoma immunotherapy. Studies have shown that a diverse panel of macrophage-activating compounds target protein-coupled receptors (GPCRs), enzymes, kinases, nuclear hormone receptors (NHRs), and transporters, which adds to the molecular basis of macrophage plasticity. However, more new pathways and targets are needed to explore the mechanism of macrophage activation, which will shed light on the underlying molecular mechanisms and help a lot in disease intervention.
Fig.1 Metabolic reprogramming in M1 and M2 macrophage. (Ho, 2016)
Based on our advanced Macrophage Therapeutics Development Platform, Creative Biolabs provides high-quality New Compounds Screening Services for Macrophage Reprogramming. By screening our large natural and synthetic compound library, many compounds for M1 or M2 activation have been identified. Meanwhile, after transcriptional analysis of macrophages treated with compounds, many known pathways, such as cytokine, and new pathways that mediate macrophage activation could be obtained. The ligands of these pathways activate macrophages by regulating gene expression of M1or M2 Macrophages. In this process, many protein targets for M1-activating compounds and M2-activating compounds could be identified. This strategy for identifying targets for macrophage activation provides a basis for choosing the most suitable compound to reprogram macrophages for precision disease intervention.
Creative Biolabs combines industry-leading expertise with our innovative platform to provide high-quality target identification services for macrophage reprogramming. Our scientists are more than happy to share our experience and help our clients with their meaningful projects. For more detailed information, please feel free to contact us or send us your inquiry or question.